Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Profusa ( (PFSA) ) just unveiled an update.
On April 21, 2026, Profusa Inc. agreed to acquire substantially all know-how assets related to Bio Insights LLC’s PanOmics Assay, an integrated NGS multi-omics platform for drug discovery and precision medicine, for $30 million in Series A Convertible Preferred Stock, excluding patent rights and biological samples but with an exclusive clinical validation sample license. The deal, which carries no assumed liabilities and includes a 3% royalty on net revenue, multi-year non-compete and transition obligations, a five-year lock-up on securities, and is contingent on Nasdaq-driven shareholder approval before a September 30, 2026 outside date, is structured as a private placement to an accredited investor under Regulation D.
The purchase price will be paid in non-voting preferred stock convertible into common shares one year after issuance, with conversion based on the prior-day closing price and subject to phased lock-up releases over five years. Profusa has also agreed to provide customary registration rights for the resale of the conversion shares, hold a shareholder meeting by June 30, 2026, and rely on a voting agreement committing the seller to support the board’s recommendations.
More about Profusa
Profusa Inc. operates in the life sciences and precision medicine sector, focusing on technologies that enable advanced biological measurement and analysis to support drug discovery and clinical applications. The company leverages integrated assay and data platforms to address pharmaceutical and research markets that rely on multi-omics and next-generation sequencing tools.
Average Trading Volume: 4,745,823
Technical Sentiment Signal: Sell
Current Market Cap: $2.54M
See more data about PFSA stock on TipRanks’ Stock Analysis page.